Screening and identification of potential inhibitor for visceral leishmaniasis (VL) through computational analysis

N. Shaslinah1†, P. Sangavi1, R. Sangeetha2, S. Gowthamkumar3†, V. Sindhu3 and K. Langeswaran1*

Abstract

Aim: The aim of this investigation is to detect potential inhibitor for visceral leishmaniasis through computational analysis.

Background: Leishmaniasis is categorized as a vector born pathogenic infection prevalent in tropical, subtropical, and in Mediterranean zones spread by intra-macrophage protozoa. The clinical syndrome of leishmaniasis is divided into the following type’s namely cutaneous leishmaniasis, mucocutaneous leishmaniasis, visceral leishmaniasis, and dermal leishmaniasis. Trypanothione synthetase is a key enzyme involving in glutathione biosynthesis as well as hydrolysis. Trypanothione is one of the promising drug targets for parasites. Parasites are inimitable with concern to their dependence on trypanothione to regulate intracellular thiol-redox balance in fighting against oxidative stress and biochemical anxiety. However, trypanothione synthetase was presumed as the target therapeutic alternate in VL therapy.

Objective: The important objective of this current investigation is to identify or analyze the potential inhibitor for V. leishmaniasis through computational approaches which include virtual screening, molecular docking, ADME prediction, and molecular dynamic simulation.

Methods: An investigation was performed to develop a 3D protein structure, using computational screening among associated similar structured proteins from popular compound database banks such as Specs, Maybridge, and Enamine, to detect novel staging with a series of validation for emerging innovative drugs molecules. Modeled protein ligand complex was further analyzed to know the binding ability of the complex. Molecular dynamics were performed to ascertain its stability at 50 ns.

Results: Trypanothione synthetase overall ability in the outcome of series of analysis. Among three database compounds screened, the compound from the Specs database exhibited the better protein-ligand docking scores and fulfilled the drug-like properties through ADMET analysis, and the docked complexes had better stability throughout the simulation. Besides, the other two database leads fulfilled the pharmacological properties, and the complexes were stable in the simulation.

Conclusion: By analyzing the various compounds from different databases, we concluded that the Specs database compound exhibits potential activity against the target protein and is considered a promising inhibitor for trypanothione synthetase.
Keywords: Trypanothione synthetase, CASTp, Visceral leishmaniasis, Molecular docking, Molecular dynamics, Binding free energy, ADME prediction

Introduction
Visceral leishmaniasis (VL) is a dangerous destructive syndrome, among different kinds of leishmaniasis. Other names of VL are Kala-Azar, black fever, or Dumdum fever [1]. VL is caused by the *Leishmania donovani* which is considered a fatal systemic disease if remained untreated. The characteristic features of VL transmission are two dissimilar ways. Zoonotic VL transmission is transferred through animals towards vector human and anthropogenic transmission is from human to vector to human. Unique clinical features of VL include lengthen fever, a sudden weight loss, liver inflammation, and increased signs of anemia, resulting in more complications due to the following cosmopolitan infections. It intruded into the microphages and multiplied in it, to attack and target reticuloendothelial systems covering the liver, spleen, and bone marrows [2]. Albeit affirmed instances of VL have been accounted for from 66 nations, 90% of the world’s VL trouble happens on the Indian subcontinent and in Sudan. The existing pattern of leishmania is completed in two hosts: one is the vertebrate host, and another is the invertebrate host [3]. Ultimately, the mortality was caused by the fragile immunological capability of the infected patient. The metabolism of thiol-dependent redox, distinctive features of metabolism that differentiate trypanosomatids from human beings, provides constant biological drug target for the designing of potential medications. Trypanosomatids, flavoenzyme trypanothione reductase, and trypanothione are supported to the homeostasis of intracellular redox [4]. Trypanothione (bis(glutathionyl)spermidine, TS2—trypanothione’s oxidized form, T(SH)2—the compact type of trypanothione, could be a necessary molecule for modulating the parasite’s oxidative stress. Synthesis of trypanothione is catalyzed by dual significant enzymes: trypanothione synthetase (TryS) and trypanothione reductase (TryR). Two ATP molecules are provided energy which is employed to the spermidine from one molecule and glutathione from two molecules. TryS is accountable for the production of trypanothione. TryR maintains its reduced form T (SH) 2 in trypanothione using the NADPH as a cofactor. NADPH is often provided by the oxidative phase of the pentose phosphate pathway through glucose 6-phosphate dehydrogenase [5]. Trypanothione T (SH) 2 reduced forms are employed by the tryparedoxin/tryparedoxin peroxidase system (TXN/TXNPx) to reduce hydrogen peroxide, alkyl-hydroperoxide, and other reactive oxygen species produced by the macrophage [6]. TryR, TryS, and TXN/TXNPx are mandatory for the survival of parasites by protecting them against oxidative stress. Trypanothione pathway is absent in humans but necessary for the survival of parasites; hence, they are categorized as antileishmanial drug target [7]. Under these conditions, TryS remains the most promising target because leishmania is a low-abundance, essential enzyme because without any homologs of humans. The significance of TryS activity for the feasibility of the parasites has been proven in vitro and in vivo by genetic and pharmacological methods on *T. brucei* and *L. infantum*. A kinetic model of trypanothione T (SH)2 metabolism in *T. cruzi* predicted that to decrease the T(SH)2 synthesis by 50%, it is fundamental either to inhibit TryS by 63% or over 98% of TryR. TryS modulates inhibition; it seems that might be a promising target in drug development. Besides, TryS has several benefits as a molecular target candidate in drug development; it is encoded by a single copy gene; the TryS structure of *L. major* has been clarified, TryS has been publicized to afford metabolic regulator to the trypanothione pathway in *T. cruzi*, and kinetic evidence is obtainable for multiple TryS.

Spermidine and 2 glutathione is joined to form T(SH)2 (disulfide-hydroperoxidase). This formation catalyzes the enzyme name trypanothione synthetase. Next, it forms the T(SH)2 which catalyzes trypanothione reductase (TryR). The TS2 is converted into T(SH)2, and T(SH)2 is converted into TS2. So, it is called a reverse reaction. Again, T(SH)2 is reduced into tryparedoxin. A thiol redox reaction is involved that time; the mammal host is involved in different mechanisms, but the parasites do not have that mechanism; so, it is used as an inhibitor. Again, TS2 is converted into T (SH)2; this formation catalyzes the enzyme which is reductase; then, it converted into tryparedoxin which catalyzes the enzyme which is peroxidase; it leads to the antioxidant defense. In mammals, GSSG is converted into GSH. Both reactions are only inhibited by trypanothione synthetase. In the present investigation, it was aimed to find trypanothione synthetase inhibitors using virtual screening and molecular dynamic simulation techniques to evaluate their ability to be used as inhibitors to the specific VL disease. This current examination additionally engaged with homology demonstrating in Swiss port model and ADME
property to locate the physicochemical property for the recognized potential compounds.

**Materials and methods**

In this study, computational analysis had done on the Intel core TM 2, 160 GB hard disk, and Linux enterprise version 5.0 as OS. In this study, Uniprot, protein BLAST, structure analysis, and verification server; sitemap, GROMACS, virtual screening workflow, and glide module; and ADME prediction was carried out to find the potential inhibitor for leishmaniasis.

**Sequence analysis**

Trypanothione syntheses were compared in the blast search using the BLASTp algorithm, which is used for aligning the target sequence against the PDB [8]. The BLAST result shows high identity and query coverage with the protein sequence database in the PDB database. Thus, we performed protein homology modeling in prime (Schrodinger suite) using trypanothione synthetase.

**Assessment of the model**

For assessing the overall stereochemical quality of the modeled protein, SAVES [9] was used for structure analysis. PROCHECK program was used for stereochemical excellence of the modeled protein structure and overall structural geometry, and the structure was refined by the GALAXY [10] server. The simulated 3D model was evaluated for its stereochemical quality by Ramachandran plot using PROCHECK, and root-mean-square deviation (RMSD) value was noted. Prosa was utilized to obtain a z-score of Ramachandran plot; the verify 3D was used to determine the compatibility of an atomic model (3D) with its location and environment and comparing the result to the good structure.

**Molecular dynamics of trypanothione synthetase putative**

Molecular dynamic (MD) simulations were done to analyze the stability of the modeled protein. MD is the computational simulation of the physical movement of atoms and molecules. GROMACS (GROningen Machine for Chemical Simulation) is a molecular dynamics package, which is assigned for simulations of protein, lipids, and nucleic acid. MD simulations were carried out using the GROMACS 4.6.3 package, GROMOS96 43a1 force field. Trypanothione synthetase solution was done in a cubic box and the SPC12 water model. Energy minimized complexes were subjected to 50 ns position restraining simulation to relieve close contact which included NVT and NPT equilibration phases also. During these equilibration phases, leapfrog integrator was used for 50 ns simulations. Coordinates, velocities, and energies were updated every 0.2 Ps with a LINCS algorithm to constrain bond lengths. Finally, 50 ns production phase MD was performed at the NPT canonical ensemble.

**Protein preparation**

The planning wizard technique was used to design the protein structure. It involved a preparatory process and its refinements. During this event, parent carbon particles were put in with hydrogen (H2) molecules, whereas unnecessary water molecules were avoided and removed. Impact refinement module OPLS-2005 power field was applied to minimize, and it closed when RMSD reached out of 0.30Å, due to it ensuring quality, vitality, and dependability for using further analysis [11].

**Virtual screening**

This is a computational-based screening approach that helps to frame or design novel drugs using screening of a large number of chemical compounds, which is obtained from different databases. It is also helpful to find the active site of target receptors. The finding of active sites in target protein is a prime task and initiative point of virtual screening. Development of grid at the active site pocket was determined by the site map module [12]. Screening of chemical compounds was initiated using XP (extra precision) docking by employing a slide module. A computational search was performed to find possible conformations. Conjugate gradient (CG) minimization with steepest descent minimization along with a default value was found to be about 0.05 Å at the initial, followed by 1.0 Å for reaching maximum extent. Based on the convergence grouping, energy charge and gradient criteria altogether were determined, and the default value was recorded to be 107 and 0.001 kcal/mol respectively. The abovementioned criteria were accounted for proceeding docking techniques, and glide score was considered to prioritize the best conformations to the selected ligands.

**Preparation of ligand**

Ligands were filtered from three different databases (Enamine, Maybridge, Specs). Based on the highest glide score, glide energy, and some essential criteria, some of the ligands were selected, and those ligands were prepared using LigPrep modules using Merck molecular force field [13]. Ligand preparation using MMFF involved the development or conversion of 2D structure to 3D of ligand molecules in the optimized potential for liquid simulation for a field. By admitting hydrogen atoms, ligand bond orders were measured to neutralize. Minimization was also affected.
Protein active site prediction

**CASTp**
To carry out design, identifying location spot and describing and assessing concave surface regions of the 3D structure of the selected proteins, the searching pockets were detected, and it was conceded or hidden in the inner side of the proteins. Surface accessibility of the pockets and unapproachable cavities were detected and determined using the CASTp server [14].

**Prediction of MM-GBSA energy/binding energy**
To compute the prime binding energy of the searched chemical compounds, it was performed by employing MM-GBSA. This method was carried out by adapting the OPLS-2005 force field along with the GBSA solvent model sourced in Schrodinger. To analyze solvent accessible surface area, we used surface generalized born model with Gaussian surface, alternate to the Vander walls surface which was admitted [15].

The binding energy ($\Delta G_{bind}$) was derived from

$$\Delta G_{Bind} = \Delta E + \Delta G_{solv} + \Delta GSA$$

(1)

$$\Delta E = E_{complex} - E_{protein} - E_{ligand}$$

(2)

Here, $E$ denotes minimized energy value for protein-ligand complex, similarly

$$\Delta G_{solv} = \Delta G_{solv}\text{ (complex)} - \Delta G_{solv}\text{ (ligand)}$$

(3)

where $G_{solv}$ indicates salvation free energy of the complex protein inhibitor.

$$\Delta GSA = GSA\text{ (complex)} - GSA\text{ (protein)} - GSA\text{ (ligand)}$$

(4)

where $\Delta GSA$ (complex) and $\Delta GSA$ (ligand) indicated surface area energies for the complex.

**ADME prediction**
ADME prediction is the panel for finding the physicochemical and pharmacokinetic properties of the chemical compounds. The Qikprop module is used for finding the ADME properties of the lead selected compounds [17].

**Result**

**BLASTp**
Sequence similarity search for the given query sequence (Uniprot id: A0A3Q81GF4) was done by using BLASTp (retrieve the protein sequence of the target from Uniprot in FASTA format and select the sequence (PDB ID_2VOB)) to predict the 3D structure of the target protein using the Swiss model server.

**Swiss model**
It is a manifesto for contributing homology modeling to the unidentified protein structures. It is a module, providing a varied application in 3D reliable protein structure. This offers and helps to design protein structures to formulate target proteins associated with evolutionary lines (Fig. 1).

**Homology modeling and validation**
It is an effective theoretical model for determining the 3D structure for unspecified proteins. It can detect structure physical principal based on its energy and interaction. The invented model was scored using SAVE findings. Moreover, the Ramachandran plot illustrated and deciphered phi and psi angles for residual amino acids in the specified region of trypanothione synthetase (Fig. 2a, b). Our present work reveals that the plot showed 93.6% amino acid residue in favor spot, 5.7% was found in the allowed segment, and 0.5% was observed in generally allowed part, while 0.2% residues observed in the disallowed region.

**MD simulation**
Selected target protein and lead compounds were subjected to examine molecular dynamic simulation measure, using GROMACS at 50 ns. The minimization of energy to the test complex was determined by the deepest descent algorithm and neutralized using position restrained dynamic simulation. At 50 ns, dynamic simulation of the complex was tried. The determinant characteristics such as hydrogen bond numerical, root-mean-square deviation (RMSD), and fluctuation (RMSF) were also measured by employing GROMACS [16].

**Fig. 1** 3D structure of modeled protein trypanothione putative synthetase, protein
a) Ramachandran Plot

Most favoured region (A, B, L) – 93.6% (Red colour)
Additional allowed regions (a, b, l, p) – 5.7% (Yellow colour)
Generously allowed regions (-a, -b, -l, -p) – 0.5% (Pale Yellow colour)
Disallowed regions – 0.2% (White colour)

b) Z-Score

---

Fig. 2  a) Ramachandran plot analysis. b) Z-score analysis of modeled trypanothione synthetase
Fig. 3  a) RMSD, b) RMSF and c) hydrogen bond analysis of modeled protein—trypanothione synthetase
Analysis of the stability of the modeled trypanothione synthetase protein

Trypanothione synthetase was targeted to evaluate dynamics nature at 50 ns. The potential energy has been presumed that it was stable in the MD process. The trajectory of trypanothione synthetase is known to be an involved assessment of RMSD and RMSF and for the determination of the stability of the protein (Fig. 3a–c). In the present study, the RMSD profile envisaged an average deviation was observed and reached powerful stability in the course of the simulation. Similarly, RMSF plot peaks exhibited modulation in the backbone; active cavity residue is very limited and was recorded. An increasing trend was observed in the RMSF of residues such as 450–600, due to the hidden occurrence at the loop structure. The study has been inferred that the presumed model protein of trypanothione synthetase was found to be a more powerful and stable compound. However, an average structure was taking the process further investigations.

Protein active site prediction

CASTp

The active site (binding pockets) of modeled protein was predicted by using the online prediction tool CASTp. About 23 binding pockets were predicted for the protein; among them, the top four pockets were shown in Fig. 4 and Table 1. The binding cavity of the volume and area with 1392.832 and 1342.869, respectively, can be considered for further analysis. The amino acids residing in this cavity may play a major role in the binding of ligand molecules during docking analysis. In PDBsum, we elucidated the structure of the modeled protein; the protein have 10 sheets; 2 beta alpha beta units, 14 beta hairpins, 13 beta bulges, 35 strands, 20 helices, 22 helix-helix interactions, 65 beta turns, and 5 gamma turns were identified.

Virtual screening

The hierarchical complex screening procedure was performed to identify novel inhibitors against trypanothione synthetase protein. Enamine, Maybridge, and Specs database compounds were screened against trypanothione synthetase modeled protein [18]. The screened compounds were filtered out with LigPrep modules. The residues present in the active site are TYP_324, ASP_285, LYS_36, ARG_383, ASN_384, TYR_324, GLN_322, PHE_11, and SER_42. Grid box was constructed at the dimensions of $X = -4.51$, $Y = -26.5$, and $X = -9.08$. These residues were selected for the screening analysis; the active site was generated based on the co-crystallized ligand present in the trypanothione synthetase protein structure. The lead compound from the Specs database showed the highest docking score of about $-8.702 \text{ kcal/Mol}$, the Maybridge database compound has the highest docking score of about $-6.000 \text{ kcal/Mol}$, and the Enamine database compound showed the highest docking score of about $-6.490 \text{ kcal/Mol}$ (Fig. 5 and Table 2). The hydrogen bond interactions are also crucial for the protein-ligand binding and the stability of the complexes.

Binding free energy calculation

The protein-ligand complex was evaluated by using the related post-scoring approaches in MM-GBSA. The binding energy of the lead hits is listed in Table 3. The binding strength is determined by binding free energies of the compounds; Maybridge, Enamine, and Specs databases were $-55.951$, $-52.317$, and $-58.666 \text{ Kcal/mol}$ respectively, which defines as the high binding affinity of the ligand towards the protein to inhibit the biological activity.
Fig. 5 Docking analysis of lead compound interaction with trypanothione synthetase

a) Enamine_87271

b) Maybridge_489

c) Specs_112055
The potential energy has been presumed that it stability of the trypanothione synthetase modeled protein gives 450–600 residues, with good stability due to the hidden occurrence at the loop structure. The study finally concludes that chosen trypanothione synthetase protein was found to be more stable and make a powerful complex for the further future drug discovery process. However, an average structure was taking the process further investigations.

**ADME prediction**

The selected compounds were examined for absorption, distribution, metabolism, and excretion using the Qikprop module [19, 20]. The Qikprop module containing 44 relevant pharmaceutical descriptors which include hydrogen bond donor/acceptor, octanol/water partition coefficient, Rule of Five, human oral absorption, and molecular weight. The result suggested that the selected compounds have drug-like properties or pharmaceutical relevant properties and pharmacokinetic properties. The ADME properties of four compounds were tabulated (Table 4).

**Molecular dynamic simulation**

In the molecular dynamic simulation process to examine the stability of the protein-ligand complex, this level of water molecules was scrutinized. The simulation was performed usually according to the docking score and the interaction ability of the protein-ligand complex fixed at 50 ns. In our study, the RMSD plot technique exhibited that the selected lead compound Specs_112055 contains a good stability score and found between the ranges of 20–50 ns. During the period of the simulation, with the help of RMSF, the average oscillations of the macro-molecular target protein at the residue level. The peaks of the RMSF plot indicate the final range of fluctuation in the modeled protein within the residues. The results conclude that the fluctuation rate of the trypanothione synthetase modeled protein gives 450–600 residues, with good stability due to the hidden occurrence at the loop structure. The study finally concludes that chosen trypanothione synthetase protein was found to be more stable and make a powerful complex for the further future drug discovery process. However, an average structure was taking the process further investigations.

**Discussion**

Trypanothione synthetase (TryS) is one of the essential enzymes for leishmania’s survival, so it is recognized as the important drug target for drug designing [21]. TryS is the important enzyme that is normally involved in trypanothione synthesis. It also is responsible for maintaining the polyamines level; the polyamines are an essential factor for cell differentiation and proliferation. In this study, we target TryS, to design anti-leishmanial drugs with the help of different databases. We performed sequence analysis for modeling the unknown structure of the target protein. We filtered out the lead compounds, which were screened against the target protein. Structure-based virtual screening is one of the leading techniques to develop antileishmanial drugs [22]. The virtual screening which is based on molecular docking is one of the essential factors for finding the potential inhibitor for leishmaniasis, which helps to find out the protein-ligand interactions and protein–protein interactions which were monitored by an array of intermolecular interactions [23]. Besides, we performed docking analysis to find the best-docked complex. The pharmacological properties of the lead compounds also proved that they are eligible for a drug candidate, which is proven by ADME properties. The results showed that the lead compounds from various databases exhibit their potential, as a promising inhibitor for visceral leishmaniasis.

**Conclusion**

The dataset compounds shown the interaction with Maybridge (TYP_324, ASP_285, and LYS_36), Enamine (ARG_383, ASN_384), and Specs (TYR_324, GLN_322, PHE_11,SER_42) amino acid residues, while the selected compounds interact with nitrogen, hydrogen,
Table 4 The calculation of the ADME properties of compound

| Compounds id    | M/W    | Donor HB | Acceptor HB | Qplog pw | Qplog po/w | Qplog HERG | Qpp caco | Qpp MDCK | Rule of 5 | Rule of 3 | Human oral absorption (%) |
|-----------------|--------|----------|-------------|----------|------------|------------|----------|----------|-----------|-----------|--------------------------|
| Maybridge_489   | 390.4  | 3.000    | 6.200       | 12.126   | 3.624      | -7.163     | 336.989  | 2061.0   | 0         | 0         | 93                      |
| Enamine_87271   | 235.2  | 2.250    | 3.750       | 13.319   | 1.173      | -2.791     | 309.798  | 406.122  | 0         | 0         | 78                      |
| Specs_104059    | 424.3  | 6.000    | 8.500       | 20.933   | 0.686      | -7.082     | 3.028    | 0.937    | 1         | 1         | 100                     |
OH, oxygen, HO, and amino acid residues. From this result, it is tangible that the partitioned compounds are docked to target protein. The screened compounds specs_112055 have a high docking score, high binding energy, and strong interaction with the binding cavity of the target protein. In the analysis, Specs_112055 is the promising lead compound to inhibit the activity of visceral leishmaniasis targeted protein.

**Abbreviations**

VL: Visceral leishmaniasis; TryS: Trypanothione synthetase; TryR: Trypanothione reductase; BLAST: Basic Local Alignment Searching Tool; OPLS: Optimized
Acknowledgements
The authors thankfully acknowledge the DST-FIST [SR/FST/LSI-667/2016(C)] and DST-PURSE (SR/PURSE Phase 2/38 (G)) for the infrastructure facilities.

Authors' contributions
SN designed and carried out the concept, SP and SV revised the manuscript, SR and GS contributed in the collection and interpretation of data, and LK redrafted and revised the manuscript. The authors read and approved the final manuscript.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declared that there are no competing interests.

Author details
1 Cancer Informatics Laboratory, Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India. 2 Department of Physics, Mannar Thirumalai Naicker College, Passumalai, Madurai, Tamil Nadu, India. 3 Faculty of Allied Health Sciences, Chettinad Hospital & Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, India.

Received: 20 June 2021 Accepted: 14 February 2022

References
1. Vera Izaguirre DS, Zuloaga Salcedo S, Gonzalez Sanchez PC, Sanchez Lara K, Chavez Tapia N, Hoyos Tomoka MT, Dominguez Soto L, Cuevas Gonzalez JC, Rodriguez Lobato E, Vega Memije ME (2014) Actinic prurigo: a case-control study of risk factors. Int J Dermatol 53(9):1080–1085
2. Martins-Melo FR, Carneiro Ramos AN, Heukelbach J Jr, Ribeiro ALR, Werneck GL (2018) The burden of Neglected Tropical Diseases in Brazil, 1990-2016: a subnational analysis from the Global Burden of Disease Study 2016. PLoS Negl Trop Dis 12(6):e0006559
3. Alvar J, Ván D, Bern VC, Herrero M, Desjeux P, Cano J, Jannin J, den Boer ML, WHO Leishmaniasis Control Team (2012) Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS One 7(6):e35671
4. Benitez D, Medeiros A, Fiestas L, Panizzo-Zenere EA, Maiwald F, Prousis KC, Rousski M, Calogepopoulou T, Detsis A, Jaeger T et al (2016) Identification of novel chemical scaffolds inhibiting trypanothione synthetase from pathogenic trypanosomatids. PLoS Negl Trop Dis 10:e0004617
5. Nagle AS, Khare S, Kumar AB, Supel F, Buchynskyy A, Mathison CJN, Chennamani Ne K, Pendem N, Buckner FS, Gelb MH et al (2014) Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chem Rev 114:11305–11347
6. Ilari A, Fiorillo A, Genovese I, Colotti G (2017) An update on structural insights into the enzymes of the polyamine-trypanothione pathway: targets for new drugs against leishmaniasis. Future Med Chem. 9:611–77
7. Colotti G, Baocci P, Fiorillo A, Boffi A, Poser E, Di Chiara F, Ilari A (2013) Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs. Future Med Chem 5:1861–1875
8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res. 28(1):235–242
9. Wiederstein M, Sippl MJ (2007) ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 35(Web Server issue):W407–W410
10. Jalili V, Afgan E, Gu Q, Clements D, Blankenberg D, Goecks J et al (2020) The Galaxy platform for accessible, reproducible and collaborative bio-medical analyses: 2020 update. Nucleic Acids Res 48(W1):W395–W402. https://doi.org/10.1093/nar/gkaa434
11. Schrodinger (2015) Desmond User Manual, LLC. Schrodinger Press
12. Schrodinger Inc (2018) Schrodinger Release 2018 version 1 QikProp, Schrodinger, LLC, New York
13. LigPrep, v (2015) Schrodinger. New York: LLC
14. Colotti G, Baiocco P, Fiorillo A, Boffi A, Poser E, Di Chiara F, Ilari A (2013) Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs. Future Med Chem 5:1861–1875
15. Ratafia P, Lamb ML, Saeh JC (2006) Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem 49(16):4805–4808
16. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC (2005) GROMACS: fast, flexible, and free. J Comput Chem 26(16):1701–1718
17. Li AP (2001) Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 6(7):357–366
18. Gupta S, Yadav S, Suryanarayanay V, Singh SK, Saxena JK (2017) Investigating the folding pathway and substrate induced conformational changes in B. malayi Guanylate kinase. Int J Biol Macromol 94(Pt A):621–633
19. Kumar N, Goel N, Yadav TC, Pruthi V (2017) Quantum chemical, ADMET and molecular docking studies of ferulic acid amide derivatives with a novel anticancer drug target. Med Chem Res 26:1822–1834
20. Nisha C, Kumar A, Vimal A, Bai B, Pal D, Kumar A (2016) Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor. J Mol Graph Model 65:100–107
21. Singh BK, Sarkar N, Dubey VK (2008) ISSN 0973-8916, Modeled structure of trypanothione synthetase of leishmania infantum for development of novel therapeutics for leishmaniasis. Curr Trends Biotechnol Pharm 2(2):390–395
22. Pandey RK, Sharma D, Bhatt TK, Sundar S, Prajapati VK (2015) Developing imidazole analogues as potential inhibitor forLeishmania donovani-trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach. J Biomol Struct Dyn 33(12):2541–2553. https://doi.org/10.1080/07391102.2015.1085904
23. Sahoo GC, Yousuf Ansari M, Dikhit MR, Kannan M, Rana S, Das P (2014) Structure prediction of gp21 protein of L. donovani and its molecular interaction. J Biomol Struct Dyn 32:709–729. https://doi.org/10.1080/07391102.2013.789400

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.